Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000725201 | SCV000334847 | uncertain significance | not provided | 2017-07-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000457561 | SCV000548508 | likely benign | Walker-Warburg congenital muscular dystrophy | 2024-01-30 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV000331999 | SCV000594784 | uncertain significance | not specified | 2016-06-30 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000725201 | SCV000617404 | uncertain significance | not provided | 2021-02-13 | criteria provided, single submitter | clinical testing | Immunohistochemical analysis noted a depletion of alpha-dystroglycan glycosylation and mildly reduced alpha-dystroglycan on muscle biopsy from the patient (Boito et al., 2007); In silico analysis supports that this missense variant does not alter protein structure/function; Missense variants in this gene are often considered pathogenic (Stenson et al., 2014); This variant is associated with the following publications: (PMID: 16344347, 26990548, 17952692, 30564623) |
Counsyl | RCV000664793 | SCV000788808 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2I | 2016-12-16 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000725201 | SCV001250132 | pathogenic | not provided | 2017-09-01 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000725201 | SCV001475118 | uncertain significance | not provided | 2019-11-12 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000331999 | SCV002598949 | uncertain significance | not specified | 2022-09-17 | criteria provided, single submitter | clinical testing | Variant summary: FKRP c.731G>A (p.Arg244His) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00026 in 149914 control chromosomes (gnomAD v3.1.2), predominantly at a frequency of 0.0011 within the Latino subpopulation in the gnomAD database. This frequency is not significantly higher than expected for a pathogenic variant in FKRP causing Limb-Girdle Muscular Dystrophy, Autosomal Recessive (0.00026 vs 0.0024), allowing no conclusion about variant significance. c.731G>A has been reported in the literature in at least one homozygous individual affected with mild Limb-Girdle Muscular Dystrophy (Boito_2005, Boito_2007). These data indicate that the variant may be associated with disease. Muscle biopsy analysis of this homozygous patient showed that glycosylated alpha-dystroglycan levels were 20% of what is seen in controls (Boito_2007). Eight ClinVar submitters have assessed the variant since 2014: seven classified the variant as uncertain significance and one as pathogenic. Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. |
Ambry Genetics | RCV002379117 | SCV002671039 | uncertain significance | Cardiovascular phenotype | 2024-01-19 | criteria provided, single submitter | clinical testing | The p.R244H variant (also known as c.731G>A), located in coding exon 1 of the FKRP gene, results from a G to A substitution at nucleotide position 731. The arginine at codon 244 is replaced by histidine, an amino acid with highly similar properties. This variant was reported in a homozygous individual with limb girdle muscular dystrophy, including myalgia, more affected lower limbs than upper, and no muscle hypertrophy; muscle biopsy results showed some reduction in glycosylated alpha-dystroglycan expression compared to controls (Boito CA et al. Arch. Neurol., 2005 Dec;62:1894-9; Boito CA et al. Virchows Arch., 2007 Dec;451:1047-55). This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV000725201 | SCV003832608 | uncertain significance | not provided | 2023-11-30 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000664793 | SCV001460339 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2I | 2020-01-12 | no assertion criteria provided | clinical testing |